LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Kodu・Aktsiate loetelu・Ovid therapeutics Inc

Ovid therapeutics Inc

Suletud

SektorTervishoid

2.85 2.15

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.68

Max

2.94

Põhinäitajad
By Trading Economics
Sissetulek	22M 9.7M
Müük	586K 718K
Kasumimarginaal	1,345.822
Töötajad	23
EBITDA	-152K -12M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+80.29% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. mai 2026

Turustatistika
By TradingEconomics
Turukapital	368M 507M
Eelmine avamishind	0.7
Eelmine sulgemishind	2.85

Uudiste sentiment

By Acuity

50%

150 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.275 / 0.33 Toetus ja vastupanu

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2026, 22:50 UTC

Tulu

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. mai 2026, 22:49 UTC

Tulu

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. mai 2026, 22:32 UTC

Tulu

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. mai 2026, 22:57 UTC

Market Talk

Tulu

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. mai 2026, 22:26 UTC

Tulu

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure Interim Dividend A$0.50/Security

12. mai 2026, 22:24 UTC

Tulu

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. mai 2026, 22:19 UTC

Tulu

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. mai 2026, 22:13 UTC

Tulu

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. mai 2026, 22:11 UTC

Tulu

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. mai 2026, 22:11 UTC

Tulu

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. mai 2026, 22:10 UTC

Tulu

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. mai 2026, 22:08 UTC

Tulu

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. mai 2026, 22:07 UTC

Tulu

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. mai 2026, 22:05 UTC

Tulu

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

80.29% tõus

12 kuu keskmine prognoos

Keskmine 5.03 USD 80.29%

Kõrge 7 USD

Madal 4 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Ovid therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

150 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.